PRO31 MEDICAL INNOVATION ASSESSMENT AND ECONOMIC BURDEN OF DISEASES ON THE EXAMPLE OF RARE AND COMMON DISEASES IN POLAND

Abstract

Conducting studies on economic burden of diseases in the process of medical innovation implementation is extremely important. We examined the benefits and costs of implementing innovative solutions in the case of tuberous sclerosis (TSC) treatment initiated by the Polish specialists and in the case of diabetes treatment. We have also examined the economic burden of these diseases and their comorbidities (i.a. epilepsy, hypertension). In order to estimate the benefits and costs of preventive antiepileptic treatment in TSC patients (i.e. vigabatrin) datasets from the Department of Neurology and Epileptology in the Children’s Memorial Health Institute in Warsaw were used. Benefits and costs of incretin-based therapies were estimated on the basis of the data from the National Health Fund (NHF), taking into account the patients who would benefit most from their use (i.a. data on the number of patients suffering from cardiovascular complications of diabetes). In order to estimate the direct medical costs of disorders, data from the NHF were used with related etiological fraction calculus and sensitivity analysis. Indirect costs were calculated upon Social Insurance Institution and Central Statistical Office datasets using human capital method. The total cost of TSC and its complications, taking into account sensitivity analysis, amounts to: EUR 2.1 million-EUR 3.3 million. The implementation of preventive antiepileptic treatment in TSC patients will reduce the costs of complications by at least EUR 2.7 million. The total cost of diabetes and its complications amounts to EUR 1.6 billion. The minimum cost of incretin-based therapies amounts to EUR 71 million. The implementation of incretin reimbursement will reduce the costs of complications by at least EUR 351.4 million. The societal and long-term perspective is crucial in the process of medical innovation implementation. The introduction of innovative therapy is associated with a reduction in the incidence and costs of serious complications.